PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN A REAL LIFE POPULATION: COMPARISON WITH TRIAL FINDINGS  by Jakobsen, Lars et al.
    
 i2 SUMMIT   
A198.E1857 
JACC March 9, 2010
Volume 55, issue 10A
PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN A REAL LIFE POPULATION: COMPARISON 
WITH TRIAL FINDINGS
i2 Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 3:30 p.m.-4:30 p.m.
Session Title: DES II, Restenosis, Left Main and Outcomes
Abstract Category: Outcomes/Operator Volume/Public Reporting/Misc. Topics/Guidelines
Presentation Number: 2502-518
Authors: Lars Jakobsen, Troels Niemann, Torsten Toftegaard Nielsen, Niels Thorsgaard Pedersen, Søren Paaske Johnsen, Department of Clinical 
epidemiology, Aarhus University Hospital, Aarhus, PE, Denmark, Department of Internal Medicine & Cardiology, Herning Hospital, Herning, Denmark
Background: Primary percutaneous coronary intervention (pPCI) is the recommended treatment of ST-Elevation Myocardial Infarction (STEMI). The 
efficacy of pPCI is documented in a number of randomised controlled trials, among these the Danish DANAMI-2 trial. However, translating RCT results 
into real life settings is a challenge as the external validity is often impaired.
Methods: We did a population-based follow-up study in the Central Denmark Region. We compared 1320 consecutive patients from West Danish 
Heart Registry treated with pPCI between April 2004 and December 2006 to the 686 patients treated with pPCI in the DANAMI-2 trial. By reviewing 
medical records we determined whether the real-life patients were eligible in the DANAMI-2 trial. The main outcome measure was the composite 
endpoint of all-cause mortality, reinfarction and stroke at 30 days, 1 and 2 years. We used Cox proportional hazards regression to compute crude 
and adjusted hazard ratios adjusting for differences in patient characteristics, duration of symptoms, type of stent and the use of cardiovascular 
drugs after one year.
Results: The real-life population had a more adverse baseline risk profile including older age, higher comorbidity, longer duration of symptoms 
and a higher prevalence of 3-vessel disease. The cumulative incidence of the composite endpoint after 1 and 2 years was 17.8 % and 22.0 % 
respectively in the real-life population compared with 13.6 % and 17.3 % in the DANAMI-2 population. After adjustment the differences persisted 
after 1 year (adjusted HR=1.8, 95% CI: 1.3-2.6), and 2 years (adjusted HR=1.7, 95% CI: 1.2-2.3). The results in the real-life patients eligible 
according to the DANAMI-2 criteria were comparable to the results in the DANAMI-2 trial.
Conclusion: Real-life patients had a more adverse baseline prognostic profile and a poorer clinical outcome compared with the DANAMI-2 
patients. However, the prognosis in the real-life patients eligible according to the DANAMI-2 criteria was comparable to that for the DANAMI-2 
patients.
